Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1881-1900 of 3,900 trials

Myotonic Dystrophy: Long-Term Study of Mexiletine PR

We are examining the long-term safety and effectiveness of mexiletine PR for treating myotonia in patients with myotonic dystrophy types 1 and 2. This study is for those who have completed a prior related study.

Myotonic Dystrophy1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

Myotonic Dystrophy: Mexiletine PR Study

We are investigating whether once daily mexiletine can help reduce muscle stiffness in patients with myotonic dystrophy types 1 and 2. The study will also look at its safety and how it affects daily activities.

Myotonic Dystrophy6-12 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Childhood Cancer: Vaccine Response Study for Measles and Chickenpox

We are examining how well children and teens with a history of childhood cancer respond to vaccines for measles and chickenpox after treatment. This study aims to understand their immunity levels and how treatment affects their ability to fight these diseases.

Pediatric Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesOncologyPediatrics

Cystic Fibrosis: SPL84 Inhalation Treatment

We are testing a new inhaled medication, SPL84, for patients with cystic fibrosis to see if it is safe and how well it works. This study will help us understand its effects on this specific group of patients.

Cystic Fibrosis3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesInternal MedicinePulmonology

Multiple Myeloma: Anitocabtagene Autoleucel Study

We are comparing a new treatment called anitocabtagene autoleucel with standard therapies for patients with relapsed or refractory multiple myeloma. The goal is to see which option works better and is safer for patients.

Relapsed/Refractory Multiple MyelomaConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

HIV Treatment: Combination Therapy Study

We are investigating a combination of three drugs to see if they can help reactivate HIV in people living with the virus. This study aims to understand the safety and effectiveness of these treatments.

HIV-1≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal Medicine

Yellow Fever and Rabies: Investigational Vaccines

We are testing two new vaccines for yellow fever and rabies in healthy adults aged 18 to 40. The study aims to evaluate their safety and how well they trigger an immune response.

RabiesYellow FeverSafety phase (I)Infectious Diseases

AMG 193 for Advanced Gastrointestinal and Pancreatic Cancers

We are testing AMG 193 combined with other therapies for patients with advanced gastrointestinal, biliary tract, or pancreatic cancers that have a specific genetic deletion. The goal is to see if this combination improves treatment outcomes.

Biliary and Pancreatic Cancer>2 yearsSafety phase (I)Oncology

Hereditary Transthyretin-Mediated Amyloid Polyneuropathy: ION-682884 Study

We are assessing the long-term safety and effectiveness of ION-682884 in patients with hereditary transthyretin-mediated amyloid polyneuropathy. This study aims to understand how well the treatment works over time.

Familial Amyloid PolyneuropathyConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNeurology

Non-Small Cell Lung Cancer: U3-1402 Treatment

We are studying a new treatment called U3-1402 for individuals with non-small cell lung cancer. The goal is to see how well it works compared to current therapies.

Metastatic Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Breast Cancer: Abemaciclib with Endocrine Therapy

We are studying a combination of Abemaciclib and endocrine therapy for patients with advanced hormone receptor positive HER2 negative breast cancer. The trial focuses on how well this treatment works and how we can manage side effects using digital tools.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsMonitoring phase (IV)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Solid Tumors: NECVAX-NEO1 with PD-1/PD-L1 Therapy

We are studying a new treatment, NECVAX-NEO1, for patients with solid tumors already on PD-1 or PD-L1 therapy. The trial aims to assess its safety and how well it may work in combination with existing treatments.

Advanced Solid Tumors6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Celiac Disease: Amlitelimab Treatment Study

We are investigating whether amlitelimab can help adults with non-responsive celiac disease improve their symptoms and intestinal health while on a gluten-free diet. The study also examines the safety of this new treatment.

Coeliac Disease6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Solid Tumors: New Oral Anti-Tumor Treatment

We are testing a new oral medication for patients with solid tumors. The goal is to see if it works better than current treatments.

Advanced Solid TumorsSafety phase (I)Oncology

Epithelial Ovarian Cancer: Letrozole Maintenance Therapy

We are studying whether letrozole can help women with epithelial ovarian cancer stay cancer-free after surgery and chemotherapy. This trial compares letrozole to a placebo to see if it improves outcomes.

Ovarian Epithelial CancerConfirmation phase (III)11-15 visitsInvestigational MedicinesGynecology and ObstetricsOncology

Parkinson’s Disease and Multiple System Atrophy: Exidavnemab Study

We are testing the safety and tolerability of a new treatment called exidavnemab in patients with Parkinson’s disease and Multiple System Atrophy. This study will help us understand how well different doses are accepted by patients.

Parkinson's DiseaseMultiple System Atrophy6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteNeurology

Carpal Tunnel Syndrome: Injection vs. Surgery

We are comparing the effectiveness of ultrasound-guided injections to surgery for treating carpal tunnel syndrome. This study will help determine which approach may be better for patients in the long run.

Carpal Tunnel Syndrome>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyOrthopedics and Traumatology

THEO-260 for Ovarian Cancer Treatment

We are studying a new treatment for patients with high-grade serous or endometrioid ovarian cancer to see if it is safe and effective. This trial will help us understand the best dose and how well it works compared to existing options.

Ovarian Cancer>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Advanced Solid Tumors: LY4170156 Treatment

We are studying a new treatment called LY4170156 for people with advanced solid tumors. The goal is to understand its safety and how well it works compared to current options.

Solid Tumors>2 yearsSafety phase (I)Oncology

Non-Small Cell Lung Cancer: Alectinib and Chemotherapy Study

We are investigating how well alectinib combined with chemotherapy works for patients with early-stage non-small cell lung cancer. This study focuses on those whose cancer can be surgically removed and who have specific biomarker characteristics.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology